ATE305810T1 - Fettsäure enthaltende pharmazeutische zusammensetzung die wenigstens 80 gew. epa und dha enthält - Google Patents

Fettsäure enthaltende pharmazeutische zusammensetzung die wenigstens 80 gew. epa und dha enthält

Info

Publication number
ATE305810T1
ATE305810T1 AT00110811T AT00110811T ATE305810T1 AT E305810 T1 ATE305810 T1 AT E305810T1 AT 00110811 T AT00110811 T AT 00110811T AT 00110811 T AT00110811 T AT 00110811T AT E305810 T1 ATE305810 T1 AT E305810T1
Authority
AT
Austria
Prior art keywords
dha
epa
acid
omega
pharmaceutical composition
Prior art date
Application number
AT00110811T
Other languages
English (en)
Inventor
Hajime Shibuya
Original Assignee
Pro Aparts Investimentos E Con
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=8168789&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ATE305810(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Pro Aparts Investimentos E Con filed Critical Pro Aparts Investimentos E Con
Application granted granted Critical
Publication of ATE305810T1 publication Critical patent/ATE305810T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
AT00110811T 2000-05-22 2000-05-22 Fettsäure enthaltende pharmazeutische zusammensetzung die wenigstens 80 gew. epa und dha enthält ATE305810T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP00110811A EP1157692B1 (de) 2000-05-22 2000-05-22 Fettsäure enthaltende pharmazeutische Zusammensetzung die wenigstens 80 Gew. % EPA und DHA enthält

Publications (1)

Publication Number Publication Date
ATE305810T1 true ATE305810T1 (de) 2005-10-15

Family

ID=8168789

Family Applications (1)

Application Number Title Priority Date Filing Date
AT00110811T ATE305810T1 (de) 2000-05-22 2000-05-22 Fettsäure enthaltende pharmazeutische zusammensetzung die wenigstens 80 gew. epa und dha enthält

Country Status (6)

Country Link
EP (1) EP1157692B1 (de)
AT (1) ATE305810T1 (de)
DE (1) DE60022987T2 (de)
DK (1) DK1157692T3 (de)
ES (1) ES2246769T3 (de)
PL (1) PL347655A1 (de)

Families Citing this family (72)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9901809D0 (en) 1999-01-27 1999-03-17 Scarista Limited Highly purified ethgyl epa and other epa derivatives for psychiatric and neurological disorderes
ITMI20010129A1 (it) 2001-01-25 2002-07-25 Pharmacia & Upjohn Spa Acidi grassi essenziali nella terapia di insufficienza cardiaca e scompenso cardiaco
ITMI20012384A1 (it) 2001-11-12 2003-05-12 Quatex Nv Uso di acidi grassi poliinsaturi per la prevenzione primaria di eventi cardiovascolari maggiori
ITMI20020269A1 (it) * 2002-02-12 2003-08-12 Victorix Assets Ltd Uso di steri etilici di acidi poliinsaturi omega-3 in pazienti con insufficienza cardiaca
ITMI20022511A1 (it) * 2002-11-26 2004-05-27 Victorix Assets Ltd Uso di composizioni farmaceutiche contenenti esteri etilici di acidi poliinsaturi omega-3 nella orevenzione della fibrillazione atriale.
ES2209658B1 (es) * 2002-12-05 2005-10-01 Proyecto Empresarial Brudy, S.L. Utilizacion del acido docosahexaenoico como principio activo para el tratamiento de la lipodistrofia.
ITMI20040069A1 (it) 2004-01-21 2004-04-21 Tiberio Bruzzese Uso di composizioni di acidi grassi n-3 ad elevata concentrazione per il trattamento di disturbi del sistema nervoso centrale
US8114906B2 (en) * 2004-04-16 2012-02-14 Abbott Products Gmbh Essential fatty acids in the treatment and/or inhibition of depression in patients with coronary heart or artery disease
JP2008509154A (ja) 2004-08-06 2008-03-27 トランスフオーム・フアーマシユーチカルズ・インコーポレーテツド 新規なスタチン薬剤組成物および関連治療方法
FR2878747B1 (fr) * 2004-12-03 2007-03-30 Pierre Fabre Medicament Sa Utilisation d'acide(s) gras omega-3 pour le traitement de l'hypercholesterolemie causee par un traitement anti-retroviral chez les patients infectes par le vih
US8324276B2 (en) 2005-01-24 2012-12-04 Pronova Biopharma Norge As Fatty acid composition for treatment of alzheimer's disease and cognitive dysfunction
ITMI20051560A1 (it) * 2005-08-10 2007-02-11 Tiberio Bruzzese Composizione di acidi grassi n-3 con elevata concentrazione di epa e-o dha e contenente acidi grassi n-6
NZ569068A (en) 2005-12-20 2011-11-25 Cenestra Llc Omega 3 fatty acid formulations of EPA and DHA
EP2081550B2 (de) 2006-03-09 2021-05-26 Reliant Pharmaceuticals, Inc. Beschichtung von kapseln mit pharmazeutischen wirkstoffen
CA2653787C (en) 2006-05-31 2016-06-21 Mochida Pharmaceutical Co., Ltd. Composition for preventing the occurrence of cardiovascular event in multiple risk patient
FR2902659A1 (fr) 2006-06-23 2007-12-28 Pierre Fabre Medicament Sa Ester de dha et son utilisation dans le traitement et la prevention des maladies cardiovasculaires
AU2008272135B2 (en) * 2007-06-29 2013-10-31 Takeda Pharmaceutical Company Limited Seamless capsule
US20090182049A1 (en) * 2008-01-16 2009-07-16 Joar Arild Opheim Pharmaceutical Composition and Method for Treating Hypertriglyceridemia and Hypercholesterolemia in Humans
WO2010028067A1 (en) 2008-09-02 2010-03-11 Amarin Corporation Plc Pharmaceutical composition comprising eicosapentaenoic acid and nicotinic acid and methods of using same
US20100062057A1 (en) * 2008-09-10 2010-03-11 Pronova BioPharma Norge AS. Formulation
KR101383006B1 (ko) 2009-02-10 2014-04-08 아마린 파마, 인크. 고중성지방혈증 치료 방법
ES2894340T3 (es) * 2009-03-09 2022-02-14 Basf As Composiciones que comprenden una mezcla de aceites de ácidos grasos y un tensioactivo, y métodos y usos de las mismas
SG175390A1 (en) 2009-04-29 2011-12-29 Amarin Corp Plc Pharmaceutical compositions comprising epa and a cardiovascular agent and methods of using the same
PT3278665T (pt) 2009-04-29 2020-11-19 Amarin Pharmaceuticals Ie Ltd Composição farmacêutica estável e métodos de utilização das mesmas
US20110196383A1 (en) * 2009-05-05 2011-08-11 Atherolysis Medical, Inc Atherosclerotic Plaque Dissolution Composition
CN106074486A (zh) 2009-06-15 2016-11-09 阿马里纳药物爱尔兰有限公司 在相伴他汀类疗法的对象中降低甘油三酯、没有增加ldl‑c水平的组合物和方法
US20110071176A1 (en) 2009-09-23 2011-03-24 Amarin Pharma, Inc. Pharmaceutical composition comprising omega-3 fatty acid and hydroxy-derivative of a statin and methods of using same
US20110082205A1 (en) * 2009-10-01 2011-04-07 Panker Cynthia A Docosahexaenoic Acid Gel Caps
US9370493B2 (en) * 2009-10-23 2016-06-21 Pronova Biopharma Norge As Coated capsules and tablets of a fatty acid oil mixture
AU2013204090B2 (en) * 2009-12-30 2015-01-29 Basf Pharma (Callanish) Limited Simulated moving bed chromatographic separation process
PE20130491A1 (es) * 2009-12-30 2013-05-02 Basf Pharma Callanish Ltd Proceso simulado de separacion cromatografica de lecho movil para la purificacion de acidos grasos poliinsaturados
WO2012032414A2 (en) * 2010-09-08 2012-03-15 Pronova Biopharma Norge As Compositions comprising a fatty acid oil mixture, a surfactant, and a statin
US20140017308A1 (en) * 2010-09-08 2014-01-16 Pronova Biopharma Norge As Compositions comprising a fatty acid oil mixture, a free fatty acid, and a statin
US20140004186A1 (en) * 2010-09-08 2014-01-02 Pronova Biopharma Norge As Compositions comprising a fatty acid oil mixture comprising epa and dha in free acid form, a surfactant, and a statin
NZ778131A (en) 2010-11-29 2023-03-31 Amarin Pharmaceuticals Ie Ltd Low eructation composition and methods for treating and/or preventing cardiovascular disease in a subject with fish allergy/hypersensitivity
US11712429B2 (en) 2010-11-29 2023-08-01 Amarin Pharmaceuticals Ireland Limited Low eructation composition and methods for treating and/or preventing cardiovascular disease in a subject with fish allergy/hypersensitivity
GB201111589D0 (en) 2011-07-06 2011-08-24 Equateq Ltd New modified process
GB201111595D0 (en) 2011-07-06 2011-08-24 Equateq Ltd Improved process
GB201111601D0 (en) 2011-07-06 2011-08-24 Equateq Ltd New process
GB201111591D0 (en) 2011-07-06 2011-08-24 Equateq Ltd Further new process
GB201111594D0 (en) 2011-07-06 2011-08-24 Equateq Ltd New improved process
US11291643B2 (en) 2011-11-07 2022-04-05 Amarin Pharmaceuticals Ireland Limited Methods of treating hypertriglyceridemia
EP2775837A4 (de) 2011-11-07 2015-10-28 Amarin Pharmaceuticals Ie Ltd Verfahren zur behandlung von hypertriglyceridämie
ES2891473T3 (es) 2012-01-06 2022-01-28 Amarin Pharmaceuticals Ie Ltd Composiciones y métodos para reducir los niveles de alta sensibilidad (hs-CRP) en un sujeto
RS57777B1 (sr) 2012-01-06 2018-12-31 Omthera Pharmaceuticals Inc Dpa-obogaćene kompozicije omega-3 polinezasićenih masnih kiselina u obliku slobodne kiseline
EP4338805B1 (de) 2012-06-29 2025-06-04 Amarin Pharmaceuticals Ireland Limited Eicosapentaensäureethylester zur verwendung bei der verringerung des risikos eines nicht-fatalen herzinfarktes bei einer person in statin-therapie
WO2014074552A2 (en) 2012-11-06 2014-05-15 Amarin Pharmaceuticals Ireland Limited Compositions and methods for lowering triglycerides without raising ldl-c levels in a subject on concomitant statin therapy
US20140187633A1 (en) 2012-12-31 2014-07-03 Amarin Pharmaceuticals Ireland Limited Methods of treating or preventing nonalcoholic steatohepatitis and/or primary biliary cirrhosis
US9814733B2 (en) 2012-12-31 2017-11-14 A,arin Pharmaceuticals Ireland Limited Compositions comprising EPA and obeticholic acid and methods of use thereof
GB201300354D0 (en) * 2013-01-09 2013-02-20 Basf Pharma Callanish Ltd Multi-step separation process
US9452151B2 (en) 2013-02-06 2016-09-27 Amarin Pharmaceuticals Ireland Limited Methods of reducing apolipoprotein C-III
US9624492B2 (en) 2013-02-13 2017-04-18 Amarin Pharmaceuticals Ireland Limited Compositions comprising eicosapentaenoic acid and mipomersen and methods of use thereof
US9662307B2 (en) 2013-02-19 2017-05-30 The Regents Of The University Of Colorado Compositions comprising eicosapentaenoic acid and a hydroxyl compound and methods of use thereof
US9283201B2 (en) 2013-03-14 2016-03-15 Amarin Pharmaceuticals Ireland Limited Compositions and methods for treating or preventing obesity in a subject in need thereof
US20140271841A1 (en) 2013-03-15 2014-09-18 Amarin Pharmaceuticals Ireland Limited Pharmaceutical composition comprising eicosapentaenoic acid and derivatives thereof and a statin
US9428711B2 (en) 2013-05-07 2016-08-30 Groupe Novasep Chromatographic process for the production of highly purified polyunsaturated fatty acids
US8802880B1 (en) 2013-05-07 2014-08-12 Group Novasep Chromatographic process for the production of highly purified polyunsaturated fatty acids
US10966968B2 (en) 2013-06-06 2021-04-06 Amarin Pharmaceuticals Ireland Limited Co-administration of rosiglitazone and eicosapentaenoic acid or a derivative thereof
US20150065572A1 (en) 2013-09-04 2015-03-05 Amarin Pharmaceuticals Ireland Limited Methods of treating or preventing prostate cancer
US9585859B2 (en) 2013-10-10 2017-03-07 Amarin Pharmaceuticals Ireland Limited Compositions and methods for lowering triglycerides without raising LDL-C levels in a subject on concomitant statin therapy
EP2881456A1 (de) 2013-12-04 2015-06-10 Natac Pharma, S.L. Enzymatisches Verfahren zur Trennung von Phytansäure aus Fetten oder Ölen damit und zur Wiederherstellung unveränderter, phytansäurefreier Produkte
EP2883860B1 (de) 2013-12-11 2016-08-24 Novasep Process Chromatografisches Verfahren zur Herstellung von mehrfach ungesättigten Fettsäuren
JP6303017B2 (ja) 2014-01-07 2018-03-28 ノヴァセプ プロセスＮｏｖａｓｅｐ Ｐｒｏｃｅｓｓ 芳香族アミノ酸を精製する方法
US10561631B2 (en) 2014-06-11 2020-02-18 Amarin Pharmaceuticals Ireland Limited Methods of reducing RLP-C
WO2015195662A1 (en) 2014-06-16 2015-12-23 Amarin Pharmaceuticals Ireland Limited Methods of reducing or preventing oxidation of small dense ldl or membrane polyunsaturated fatty acids
CN107666904B (zh) 2015-03-26 2022-02-01 提贝托·布鲁泽塞 多不饱和脂肪酸的纯化组合物、其制备方法及其用途
US10406130B2 (en) 2016-03-15 2019-09-10 Amarin Pharmaceuticals Ireland Limited Methods of reducing or preventing oxidation of small dense LDL or membrane polyunsaturated fatty acids
WO2018213663A1 (en) 2017-05-19 2018-11-22 Amarin Pharmaceuticals Ireland Limited Compositions and methods for lowering triglycerides in a subject having reduced kidney function
US11058661B2 (en) 2018-03-02 2021-07-13 Amarin Pharmaceuticals Ireland Limited Compositions and methods for lowering triglycerides in a subject on concomitant statin therapy and having hsCRP levels of at least about 2 mg/L
KR20210110890A (ko) 2018-09-24 2021-09-09 애머린 파마슈티칼스 아일랜드 리미티드 대상체에서 심혈관 사건의 위험도를 감소시키는 방법
US12427134B2 (en) 2019-11-12 2025-09-30 Amarin Pharmaceuticals Ireland Limited Methods of reducing the risk of cardiovascular events in a subject with atrial fibrillation and/or atrial flutter
AU2022263358A1 (en) 2021-04-21 2023-11-30 Amarin Pharmaceuticals Ireland Limited Methods of reducing the risk of heart failure

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8819110D0 (en) * 1988-08-11 1988-09-14 Norsk Hydro As Antihypertensive drug & method for production

Also Published As

Publication number Publication date
PL347655A1 (en) 2001-12-03
EP1157692B1 (de) 2005-10-05
DE60022987D1 (de) 2005-11-10
DE60022987T2 (de) 2006-10-19
EP1157692A1 (de) 2001-11-28
ES2246769T3 (es) 2006-03-01
DK1157692T3 (da) 2006-02-06

Similar Documents

Publication Publication Date Title
ATE305810T1 (de) Fettsäure enthaltende pharmazeutische zusammensetzung die wenigstens 80 gew. epa und dha enthält
KR0126286B1 (ko) 지방산 조성물
BR0112680A (pt) Genes elongase e usos dos mesmos
PT1310249E (pt) Utilizacao de acidos gordos poli-insaturados para prevencao primaria de eventos cardiovasculares graves
JPH0232017A (ja) 精神分裂症および／または関連した晩発性運動障害の治療のための薬剤を製造する方法
RU2002133098A (ru) Терапевтические комбинации жирных кислот
HU198171B (en) Process for concentrating delta 6 polyinsaturated fatty acids in the mixture of polyinsaturated fatty acids
WO2000012720A3 (en) Elongase genes and uses thereof
CA2289648A1 (en) Conjugated linoleic acid compositions
JP2009526033A (ja) オメガ３
IL88239A (en) 4- (substituted- 2-benzocycloheptene -2- ylethenyl)- benzoic acid derivatives, their preparation and pharmaceutical compositions containing them
KR940018091A (ko) 불포화 지방산을 포함하는 처방
CA2362271A1 (en) Essential fatty acids in the prevention of cardiovascular events
DE69523654T2 (de) Verwendung von Ascorbyl-gamma-Linolenat und von Ascorbyl-dihomo-gamma-linolenat zur Behandlung von Asthma, Krebs, kardiovaskulären und inflammatorischen Erkrankungen
BR0013958A (pt) Dieta de elevado teor de lipìdios
KR20150131302A (ko) 구강 건조증의 치료 및 치아 치료를 위한 조성물
WO1987004926A2 (en) Method of modifying the lipid structure of cell membranes and pharmaceutical compositions for use therein
JPS58159418A (ja) 医薬組成物
KR910700248A (ko) 위산 분비 억제 효과를 갖는 화합물 및 그의 제조 방법
EP0832058A1 (de) Triglyceride
ATE179889T1 (de) Arzneimittel, die ester omega-3 polyungesättigter säuren enthalten und deren verwendung in der topischen behandlung morbider erkrankungen
HU204199B (en) Process for producing pharmaceutical compositions containing unsaturated fatty acids and selenium as active components
SE8800989D0 (sv) Dietary composition and process for preparing same
EP0283140B1 (de) Zusammensetzungen und Verfahren zur Behandlung von Magengeschwüren
US7740885B2 (en) Nutraceutical and pharmaceutical compositions and their uses

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1157692

Country of ref document: EP